Exogenous surfactant therapy for ARDS.
Regardless of the cause, a common pathophysiological feature of patients with acute respiratory distress syndrome is a dysfunction of the endogenous surfactant system. Although exogenous surfactant therapy has proven to be an effective treatment for neonatal respiratory distress syndrome, no similar current effective therapy exists for patients with acute respiratory distress syndrome. This is mainly due to the complexity of the lung injury that is involved with this disorder. Results from clinical trials, to date, have failed to show an improvement in patient survival after administration of exogenous surfactant; however, ongoing and future research efforts suggest that this therapy may eventually be feasible.
Maruscak
Adam
A
St. Joseph's Health Centre, London, ON, N6A 4V2, Canada.
Lewis
Jim F
JF
D015060:1,2-Dipalmitoylphosphatidylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage / Q000627:therapeutic use; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D006801:Humans; D037721:Pulmonary Surfactant-Associated Protein C / Q000008:administration & dosage / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate
D001688:Biological Products; D037721:Pulmonary Surfactant-Associated Protein C; D011663:Pulmonary Surfactants; D011994:Recombinant Proteins; D015060:1,2-Dipalmitoylphosphatidylcholine; C081581:colfosceril palmitate; C072197:beractant